A Study of LY3192767 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-06

Study Completion Date

2018-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to investigate the side effects related to LY3192767 when given as an injection under the skin to healthy participants. Blood tests will be done to check how much LY3192767 is absorbed into the bloodstream, how long it takes for the body to get rid of it, and how it affects blood sugar levels. The study has two parts: Part A and Part B. Each participant will enroll in one part. For each participant, Part A will last up to about 32 days after last dose and Part B will last up to about 49 days after last dose. Screening must be completed prior to study start.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Patients With Type 2 Diabetes Mellitus

NCT01435616

Diabetes Mellitus, Type 2

COMPLETED PHASE3

A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy

NCT02703337

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380

Healthy Volunteers Diabetes Mellitus, Type 1

COMPLETED PHASE1

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

NCT04957914

Type 2 Diabetes Mellitus

COMPLETED PHASE1

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

NCT01894568

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3192767 (Part A)

Escalating doses of LY3192767 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3192767

Intervention Type DRUG

Administered SC.

Placebo (Part A)

Placebo matching LY3192767 administered subcutaneously (SC).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC.

LY3192767 (Part B)

LY3192767 administered as a SC injection in one of three study periods.

Group Type EXPERIMENTAL

LY3192767

Intervention Type DRUG

Administered SC.

Basal Insulin Peglispro (Part B)

Basal insulin peglispro administered as a SC injection in one of three study periods.

Group Type ACTIVE_COMPARATOR

Basal Insulin Peglispro

Intervention Type DRUG

Administered SC.

Insulin Glargine (Part B)

Insulin glargine administered as a SC injection in one of three study periods.

Group Type ACTIVE_COMPARATOR

Insulin Glargine

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3192767

Administered SC.

Intervention Type DRUG

Basal Insulin Peglispro

Administered SC.

Intervention Type DRUG

Insulin Glargine

Administered SC.

Intervention Type DRUG

Placebo

Administered SC.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2605541

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy males or females, as determined by medical history and physical examination
* Have a body mass index (BMI) of \>18.5 and \<30.0 kilogram per square meter (kg/m²), inclusive

Exclusion Criteria

* Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
* Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
* Have participated as a participant in a first-in-human study within 90 days of the initial dose of study drug
* Have known allergies to insulin, heparin, or related drugs, or history of relevant allergic reactions of any origin
* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, chronic inflammatory disease, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data

Minimum Eligible Age

20 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes